Cegedim Health Data expands its European database THIN®with German real-world data.


THIN® (The Health Improvement Network), one of Europe’s largest real-world database now includes German anonymized electronic health records

[Copenhagen, ISPOR Europe, November 13th 2023]

Cegedim Health Data, provider of anonymized clinical real-world data (RWD) and real-world evidence (RWE), today announces the extension of the major European database THIN® to include German RWD. Already composed of data from the United Kingdom, France, Italy, Spain, Belgium and Romania, the database now includes German electronic health records (EHRs) and is available to all healthcare stakeholders, including academic researchers and healthcare authorities.

With more than 10 million active EHR per year, THIN® has already established itself as one of the most important medical data sources for anonymized longitudinal real-world data. The THIN® database now includes Europe’s five largest economies plus Belgium and Romania, and supports leading pharmaceutical companies, research organizations, academics, and health authorities with data from German general practitioners and specialist practices. THIN® is built on a common data model to enable easy comparison of information and is also recognized for its statistical robustness. THIN® therefore contributes to advancements in patient care and outcomes, in the interests of public health.

THIN® real-world data is already being used internationally by health authorities (EMA/ENCePP in Europe, NHS and NICE in the UK, and HAS, CEPS and ANSM in France), research institutions, and in more than 2,000 indexed international scientific publications. THIN® anonymized data is transmitted by a network of voluntary general practitioners and specialists' practices, who firmly believe that supporting this kind of longitudinal data observatory benefits research and medical progress. It reflects the realities of everyday treatment. With the inclusion of German EHRs, THIN® is now being expanded to enable advances in patient care and research into new treatment methods. The datasets of anonymized longitudinal data are available to both public and private stakeholders.

New standards and opportunities for healthcare research

RWD offers great potential to target unmet medical and patient needs, characterize cohorts of anonymized patients with specific features such as pathology or disease history, and improve clinical trial design. It provides patient characteristics and clinical outcomes—symptoms, diagnoses, prescriptions, treatment sequences, medical history, medical interventions, and lab test results—which can be used to conduct epidemiological studies, drug utilization studies (DUS), post authorization safety or efficacy studies (PASS/PAES), health economics and outcomes research (HEOR), marketing studies, etc. THIN® will be useful to all departments responsible for analysing health products in real-life situations.

"RWD from real-life treatments can form new standards to evaluate disease, health status or drug therapy effectiveness, and improve public health in the future”, said Ralf Patsch, Head of Cegedim Health Data business in Germany. “With the launch of the German THIN® database, we offer healthcare stakeholders the opportunity to ensure therapy success and make medicine more predictable".


“The launch of anonymized German RWD in THIN® marks an important milestone on our way to creating a strong European database based on a common data model” said Gilles Paubert, Global Head of Cegedim Health Data. “It means it is possible to make cross-national comparisons with more than 69 million EHRs in Europe, and obtain precise and reliable answers to all stakeholders’ questions across the value chain: from research and development to market access, medical, health technology assessment and marketing, with the aim of improving public health.”.


"Real-world data continues to gain importance in the US, and is also increasingly recognized in Europe for its value in the analysis of drug therapy effectiveness and side effect rates in unselected patient populations outside controlled clinical trials in clinical practice", commented Prof. Marc Freichel from the Institute of Pharmacology at Heidelberg University.


Data protection, a top priority

All the data are routinely are transmitted by a network of voluntary physicians, strictly in accordance with data protection rules, anonymized at source, and fully GDPR-compliant. Compliance is monitored by TÜV Süd data protection experts. Anonymization routines were also meticulously verified by an independent Berlin cybersecurity company and successfully certified. Healthcare authorities, universities, research centers, medical and scientific organizations as well as biotech and pharmaceutical companies are therefore assured that the real-world data complies with legal requirements.

Press Contact UK - Lindsay Meredith, Cegedim Health Data UK Head of Marketing Lindsay.Meredith@cegedimrx.co.uk 

Press Contact EU - Alexandra Laronze Cegedim, Health Data Operational Marketing & Communication Alexandra.laronze@cegedim.com 

About Cegedim Health Data: Cegedim Health Data is the health data division of Cegedim Group, an innovative technology, services and real-world data group that has specialized in healthcare for more than 50 years. It covers seven European countries, providing anonymized real-world data (RWD) cohorts and real-world evidence (RWE) to drive research and cutting-edge improvements in patient outcomes in the interests of public health. Through THIN® (The Health Improvement Network), it offers immediate access to a data history of ~30 years and millions of anonymized electronic health records. Cegedim Health Data works with researchers, health authorities, healthcare practitioners, pharma and medical device companies. It supports them in several areas notably R&D, market access, medical affairs and marketing, with the aim of improving public health. To learn more, visit www.cegedim-health-data.com.

About Cegedim: Founded in 1969, Cegedim is an innovative technology and services group in the field of digital data flow management for healthcare ecosystems and B2B, and a business software publisher for healthcare and insurance professionals. Cegedim employs more than 6,000 people in more than 10 countries and generated revenue of €555 million in 2022. Cegedim SA is listed in Paris (EURONEXT: CGM).To learn more, please visit: www.cegedim.com.